David Liu, PhD, emphasized the significant advancements in therapeutic genome editing during his plenary session at the European Society of Gene & Cell Therapy (ESGCT) 2026 in Hamburg, Germany. Liu discussed the integration of artificial intelligence into prime editing technology, showcasing how AI tools like ProteinMPNN and OptiPrime enhance the efficiency and stability of gene editing processes. He noted the remarkable clinical progress in both base and prime editing, citing successful interventions for various genetic diseases and the liberalization of regulatory policies that facilitate drug approvals.
Liu’s focus on a multi-disease therapeutic approach aims to address multiple genetic diseases with a single treatment, potentially benefiting a broader patient population. His lab’s innovative use of suppressor tRNAs could enable treatments for numerous conditions linked to premature stop codons. While optimistic about the future of gene editing, Liu acknowledged that ongoing regulatory streamlining is essential for making these therapies accessible to more patients.
Source: genengnews.com · Image: Naitō Museum of Pharmaceutical Science and Industry 20210529 01 by 先従隗始, CC0, via Wikimedia Commons
Open the full market picture for your next decision →
